Hematology
News from the FDA/CDC
FDA: Safety signal emerged with higher dose of tofacitinib in RA study
The FDA is working with Pfizer to better understand how the signal affects patients and how the drug should be used, the agency said in a...
News
ICYMI: Rivaroxaban reduces VTE incidence in ambulatory cancer patients
However, the reduction lost significance if treatment with rivaroxaban was halted.
News
Supplementary compression doesn’t improve DVT odds in critically ill
SAN DIEGO – The procedure carries few risks, aside from patient discomfort.
News
FDA approves caplacizumab for aTTP
The injection is approved in combination with plasma exchange and immunosuppressive therapy for adults with acquired thrombotic thrombocytopenia...
Conference Coverage
Biomarkers predict VTE risk with menopausal oral hormone therapy
CHICAGO – Pretreatment high D-dimer spells 500% increased VTE risk on oral hormone therapy.
News
Meta-analysis: IVIG bests anti-D on platelet count in pediatric ITP
But the clinical significance of this finding is unclear because of the lack of data on bleeding symptoms, according to authors of the meta-...
Practice Puzzler
Diagnosing Anemia
This clinical puzzle is based on O’Neil. Diagnosing and classifying anemia in adult primary care. Clinician Reviews. 2017; 27(8):28-35...
Conference Coverage
Rivaroxaban bonus: Early unmasking of occult GI cancers
MUNICH – Secondary analysis of COMPASS trial hits pay dirt.
News
Hormonal contraceptive use linked to leukemia risk in offspring
Maternal use of hormonal contraceptives close to pregnancy is associated with a small increase in the risk of nonlymphoid leukemia in offspring....
News
FDA warns against azithromycin in blood or lymph node cancers
Azithromycin can lead to relapse and death when used to prevent an inflammatory lung condition in patients with blood or lymph node cancers who...